



NDA 202439/S-021

SUPPLEMENT APPROVAL

Janssen Pharmaceuticals, Inc
Attention: Purve Patel
Director, Regulatory Affairs, Cardiovascular and Metabolism
920 US Highway 202
PO Box 300
Raritan NJ, 08869

Dear Ms. Patel:

Please refer to your Supplemental New Drug Application (sNDA) dated September 29, 2016, received September 29, 2016, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Xarelto (rivaroxaban) 15 and 20 mg tablets.

We also refer to our approval letter dated March 29, 2017 which contained the following error: language was inadvertently removed from Section 10 in the attached agreed upon labeling.

This replacement approval letter incorporates the correction of the error. The effective approval date will remain March 29, 2017, the date of the original approval letter.

This Prior Approval supplemental new drug application provides for revisions to the prescribing information. In addition to editorial revisions throughout the label, revisions have been made to Section 7 to improve clarity, organization, and to harmonize this section with other drugs in this class, as appropriate.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert), with

the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call Michael Monteleone, Associate Director for Labeling, at (301) 796-1952.

Sincerely,

{See appended electronic signature page}

Mary Ross Southworth, PharmD
Deputy Director for Safety
Division of Cardiovascular and Renal Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MARY R SOUTHWORTH
03/29/2017